Polysaccharide-Protein Conjugate Vaccines
HISTORY OF VACCINE DEVELOPMENT(2011)
摘要
It is to Karl Landsteiner that we owe the notion that the immunologic properties of nonimmunogenic ligands (haptens), including
saccharides, can be improved by covalent attachment to proteins [1]. His pioneering studies in the 1920s influenced Walter
Goebel and Oswald Avery (his colleague at the Rockefeller Institute, NY) who sought evidence that serum antibodies to the
type 3 capsular polysaccharide (CP) of pneumococci conferred protection to that pathogen [2]. These workers showed that a
synthetic disaccharide (hapten), cellubiuronic acid, bound to a protein could elicit antibodies that were both reactive with
the type 3 CP and conferred protection to mice challenged with that pathogen. At that time, purification of individual components
of bacteria was difficult and high-titered antisera were prepared by intravenous injections of whole bacteria: such serologic
reagents were multivalent. Their studies provided convincing evidence that CPs were both essential virulence factors and protective
antigens of pneumococci.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要